Alimera Sciences, Inc. (ALIM)
USD 5.54
(-0.18%)
USD 5.54
(-0.18%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.87 Million USD | 17.07% |
| 2022 | 1.6 Million USD | -40.09% |
| 2021 | 2.67 Million USD | -2.44% |
| 2020 | 2.74 Million USD | 97.55% |
| 2019 | 1.39 Million USD | -42.2% |
| 2018 | 2.4 Million USD | 59.48% |
| 2017 | 1.5 Million USD | 238.12% |
| 2016 | 446 Thousand USD | -71.26% |
| 2015 | 1.55 Million USD | -10.5% |
| 2014 | 1.73 Million USD | -2.91% |
| 2013 | 1.78 Million USD | 148.4% |
| 2012 | 719 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 725 Thousand USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 3.45 Million USD | 56.62% |
| 2024 Q1 | 2.2 Million USD | 17.4% |
| 2023 FY | 1.87 Million USD | 17.07% |
| 2023 Q3 | 1.76 Million USD | 66.82% |
| 2023 Q2 | 1.05 Million USD | -13.17% |
| 2023 Q4 | 1.87 Million USD | 6.76% |
| 2023 Q1 | 1.21 Million USD | -24.3% |
| 2022 Q2 | 1.65 Million USD | -32.46% |
| 2022 Q4 | 1.6 Million USD | -10.13% |
| 2022 Q1 | 2.45 Million USD | -8.47% |
| 2022 FY | 1.6 Million USD | -40.09% |
| 2022 Q3 | 1.78 Million USD | 7.85% |
| 2021 Q4 | 2.67 Million USD | 16.43% |
| 2021 FY | 2.67 Million USD | -2.44% |
| 2021 Q1 | 2.59 Million USD | -5.64% |
| 2021 Q2 | 2.3 Million USD | -10.96% |
| 2021 Q3 | 2.3 Million USD | -0.26% |
| 2020 Q3 | 2.52 Million USD | 28.15% |
| 2020 Q2 | 1.96 Million USD | 64.55% |
| 2020 Q1 | 1.19 Million USD | -13.96% |
| 2020 Q4 | 2.74 Million USD | 8.88% |
| 2020 FY | 2.74 Million USD | 97.55% |
| 2019 Q4 | 1.39 Million USD | -15.35% |
| 2019 Q2 | 2.14 Million USD | 15.11% |
| 2019 Q3 | 1.64 Million USD | -23.31% |
| 2019 FY | 1.39 Million USD | -42.2% |
| 2019 Q1 | 1.86 Million USD | -22.66% |
| 2018 Q3 | 1.72 Million USD | -19.54% |
| 2018 Q1 | 1.22 Million USD | -18.83% |
| 2018 FY | 2.4 Million USD | 59.48% |
| 2018 Q4 | 2.4 Million USD | 39.74% |
| 2018 Q2 | 2.13 Million USD | 74.75% |
| 2017 Q3 | 1.73 Million USD | 52.06% |
| 2017 Q2 | 1.14 Million USD | 42.52% |
| 2017 Q1 | 802 Thousand USD | 79.82% |
| 2017 FY | 1.5 Million USD | 238.12% |
| 2017 Q4 | 1.5 Million USD | -13.23% |
| 2016 Q2 | 1.21 Million USD | -10.96% |
| 2016 FY | 446 Thousand USD | -71.26% |
| 2016 Q3 | 913 Thousand USD | -24.55% |
| 2016 Q4 | 446 Thousand USD | -51.15% |
| 2016 Q1 | 1.35 Million USD | -12.44% |
| 2015 Q2 | 1.63 Million USD | -20.18% |
| 2015 FY | 1.55 Million USD | -10.5% |
| 2015 Q4 | 1.55 Million USD | -9.56% |
| 2015 Q3 | 1.71 Million USD | 4.76% |
| 2015 Q1 | 2.05 Million USD | 18.34% |
| 2014 Q2 | 1.37 Million USD | 11.18% |
| 2014 Q1 | 1.23 Million USD | -30.91% |
| 2014 FY | 1.73 Million USD | -2.91% |
| 2014 Q4 | 1.73 Million USD | 4.84% |
| 2014 Q3 | 1.65 Million USD | 20.55% |
| 2013 Q1 | 1.05 Million USD | 47.15% |
| 2013 Q4 | 1.78 Million USD | -41.06% |
| 2013 Q2 | 1.81 Million USD | 71.36% |
| 2013 FY | 1.78 Million USD | 148.4% |
| 2013 Q3 | 3.03 Million USD | 67.13% |
| 2012 Q2 | 206 Thousand USD | 0.0% |
| 2012 Q4 | 719 Thousand USD | 7.15% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q3 | 671 Thousand USD | 225.73% |
| 2012 FY | 719 Thousand USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 FY | - USD | -100.0% |
| 2006 FY | 725 Thousand USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Cosmos Health Inc. | 4.78 Million USD | 60.765% |
| Safety Shot Inc | 1.86 Million USD | -0.5% |
| Bright Green Corporation | - USD | -Infinity% |
| Embecta Corp. | 152.1 Million USD | 98.765% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 98.31% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | 72.241% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | 94.188% |
| Dynavax Technologies Corporation | 53.29 Million USD | 96.474% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 97.137% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | 83.867% |
| Pacira BioSciences, Inc. | 104.35 Million USD | 98.199% |
| PainReform Ltd. | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | 67.235% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | 67.235% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | -132.045% |
| Journey Medical Corporation | 10.2 Million USD | 81.589% |
| Alpha Teknova, Inc. | 11.59 Million USD | 83.793% |
| Procaps Group, S.A. | 96.83 Million USD | 98.06% |
| Theratechnologies Inc. | 6.06 Million USD | 69.024% |
| Harrow Health, Inc. | 10.86 Million USD | 82.709% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | 30.894% |
| Biofrontera Inc. | 10.9 Million USD | 82.774% |
| DURECT Corporation | 2.21 Million USD | 15.322% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 97.573% |
| Cronos Group Inc. | 30.33 Million USD | 93.807% |
| OptiNose, Inc. | 8.05 Million USD | 76.664% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -187899900.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | 67.029% |
| Organogenesis Holdings Inc. | 28.25 Million USD | 93.349% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | 29.812% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | 59.235% |
| Radius Health, Inc. | 278.64 Million USD | 99.326% |
| Universe Pharmaceuticals INC | 3.34 Million USD | 43.797% |
| ProPhase Labs, Inc. | 3.84 Million USD | 51.08% |
| Phibro Animal Health Corporation | 265.91 Million USD | 99.293% |
| Procaps Group S.A. | 96.83 Million USD | 98.06% |
| Alvotech | 74.43 Million USD | 97.476% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Viatris Inc. | 3.46 Billion USD | 99.946% |
| Rockwell Medical, Inc. | 5.87 Million USD | 67.995% |
| Aytu BioPharma, Inc. | 12.63 Million USD | 85.126% |
| SIGA Technologies, Inc. | 64.21 Million USD | 97.074% |
| Tilray Brands, Inc. | 252.08 Million USD | 99.255% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | 95.3% |
| Shineco, Inc. | 1.58 Million USD | -18.286% |
| PetIQ, Inc. | 159.3 Million USD | 98.821% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 1329.889% |
| Incannex Healthcare Limited | -10.01 Million USD | 118.762% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 95.094% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 37.68 Million USD | 95.014% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | -16.68% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | 58.086% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -638.74% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | 81.898% |
| Hempacco Co., Inc. | 2.54 Million USD | 26.1% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 74.43 Million USD | 97.476% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | 96.069% |
| Lantheus Holdings, Inc. | 64.02 Million USD | 97.065% |
| Currenc Group, Inc. | 732.91 Thousand USD | -156.375% |
| Kamada Ltd. | 87.74 Million USD | 97.859% |
| Indivior PLC | 141.79 Million USD | 98.675% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | -289.963% |
| Flora Growth Corp. | 8.5 Million USD | 77.915% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -638.74% |
| Evolus, Inc. | 10.99 Million USD | 82.915% |
| HUTCHMED (China) Limited | 50.25 Million USD | 96.261% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 98.225% |
| Akanda Corp. | 1.28 Million USD | -46.01% |